Ifebemtinib plus garsorasib in previously treated metastatic colorectal cancer with KRAS G12C mutation: a multicentre, randomised, phase 1b/2 trial.
Lancet OncolSep 1, 2026
Clinical ResearchOncology (Medical)
Zhengbo Song, Liming Zhu, Ying Liu et al.
✦ AI-curated · Sources linked
In 30 seconds
This multicentre, randomised phase 1b/2 trial evaluated the combination of ifebemtinib and garsorasib in patients with previously treated metastatic colorectal cancer harboring the KRAS G12C mutation. Among 51 enrolled patients, the confirmed objective response rate was 38.9% for the combination therapy compared to 16.7% for garsorasib alone, with a between-group difference of 22.2%.
Key findings
- The confirmed objective response rate was 38.9% for the combination therapy versus 16.7% for garsorasib alone.
- In the single-arm study, the confirmed objective response rate was 46.7%.
- Grade 3 treatment-related adverse events occurred in 33% of patients receiving combination therapy.
Why it matters
The study highlights a potential new treatment option for patients with KRAS G12C-mutated metastatic colorectal cancer, demonstrating improved response rates with combination therapy compared to monotherapy. This could influence treatment decisions in this challenging patient population.